3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Spinal Cord Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Muscular Atrophy
1
Medulloblastoma
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Leukemia
1
Familial ependymoma
1
Dendritic Cell Sarcoma, Interdigitating
1
Choroid Plexus Neoplasms
1
Child Nutrition Disorders
1
Central Nervous System Neoplasms
1
Cachexia
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Blast Crisis
1
Astrocytoma
1
Interventions
ostarine
3
rimabotulinumtoxinB
1
Standard of Care
1
Olanzapine
1
Enteral Nutrition
1
Cyproheptadine
1
Creatine
1
Botulinum Toxins, Type A
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Muscular Atrophy
×
Cyproheptadine
×
Clear all
NCT06175273
2025-09-18
POINT
University of Kentucky
Phase 2/3
Completed
19 enrolled